vol1 - Page 86

Page 86 Previous , Next , Original Image
Return to Index

 Subcommittee on Public Health and Welfare of the House Committee
 on Foreign and Interstate Commerce, representatives of
 pharmaceutical companiest health care organizations and medical
 researchers voiced concern that the Bureau of Narcotics and
 Dangerous Drugs (now DEA) would have virtually total authority in
 ......! determining whether drags have accepted medical uses in
 treatment° Addressing this contemn Deputy Chief Counsel for
 BNDD, Michael R_ Sonnenreich_ declared that the determination of
 accepted medical use _will be made by the medical community, n_-_/
 _Mainly our feeling is that the trigger on your schedule I drugs
 which are really different from your [Schedule] !I_ Ill and IV
 drugs [the accepted medical use reqllirement]_ It is this basic
 determination that is not made by any part of the Federal
 Government° It is made by the medical community as to whether or
 not the drug has medical use or doesn_.t. _4_-q/
 Congress_ however, never intended the definition of
 #accepted medical use in treatment _ to be limited solely to the
 medical profession itself. Deputy Chief Counsel Sonnenreich
 testified that the determination of Waccepted medical use _ could
 be based upon legal opinion_ 4_/ Such a legal opinion, he
 observed_ could be offered by a lawyers _[/ nYou donor have to be
 _!_/ Drug Abuse Control Amendments_1970: Hearings Before the
 Subcomm. on Public Health and Welfare of the Comm. on Interstate
 and Foreign Commerce House of Repres., 91st Cong. s 2d sess.
 (1970) (statement of Michael R. Sonnenreich, Deputy Chief
 Counsel) (hereinafter nHearingsR) at 698.
 __Q/ /__® at 718. S_ 692_93_ 708 (same).
 if/ at 165o

Previous , Next , Return to Index